Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

NCT05556616 is registered in ClinicalTrials.gov with Teva Branded Pharmaceutical Products R&D LLC as lead sponsor.

NCT NCT05556616
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05556616 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Phase
Phase 1
Overall status
Terminated
Start date
January 12, 2023
Completion date
June 4, 2024
Enrollment
15 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma